A randomised, placebo-controlled, double-blind, parallel-group, multicentre, phase IIa study to explore the relationship between QTcF interval at first dose (loading dose) and at steady state after treatment with AZD1305 extended-release tablets or placebo when given to patients with documented atrial fibrillation.

Trial Profile

A randomised, placebo-controlled, double-blind, parallel-group, multicentre, phase IIa study to explore the relationship between QTcF interval at first dose (loading dose) and at steady state after treatment with AZD1305 extended-release tablets or placebo when given to patients with documented atrial fibrillation.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2012

At a glance

  • Drugs AZD 1305 (Primary)
  • Indications Atrial fibrillation
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 25 Jan 2012 Actual patient number (65) added as reported by ClinicalTrials.gov.
    • 16 Nov 2011 Actual trial initiation date changed from 1 Mar 2008 to 21 Feb 2008.
    • 01 Jun 2011 Results published in the American Journal of Cardiovascular Drugs.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top